J A Cohen

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. pmc Mesenchymal stem cell transplantation in multiple sclerosis
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA Electronic address
    J Neurol Sci 333:43-9. 2013
  2. pmc Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
    Jeffrey A Cohen
    Mellen Center U 10, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Neurol 260:2023-32. 2013
  3. doi request reprint Fingolimod therapy for multiple sclerosis
    Mary A Willis
    Neurological Institute, The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Neurol 33:37-44. 2013
  4. doi request reprint Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Lancet 380:1819-28. 2012
  5. doi request reprint Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
    Jeffrey A Cohen
    Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Lancet Neurol 11:467-76. 2012
  6. doi request reprint Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
    J A Cohen
    Mellen Center U 10, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:535-41. 2009
  7. doi request reprint Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
    J A Cohen
    Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 14:370-82. 2008
  8. doi request reprint Emerging therapies for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Arch Neurol 66:821-8. 2009
  9. ncbi request reprint Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS
    J A Cohen
    Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Neurology 68:939-44. 2007
  10. doi request reprint Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 362:402-15. 2010

Detail Information

Publications26

  1. pmc Mesenchymal stem cell transplantation in multiple sclerosis
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA Electronic address
    J Neurol Sci 333:43-9. 2013
    ..Although there are several potential safety concerns, to date, the procedure has been well tolerated. Future studies that more definitively assess efficacy also will need to address several technical issues. ..
  2. pmc Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
    Jeffrey A Cohen
    Mellen Center U 10, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Neurol 260:2023-32. 2013
    ..Reductions in lesion counts and brain volume loss also favored fingolimod in these patients. In conclusion, consistently better efficacy was observed for fingolimod compared with IFN╬▓-1a across different subgroups of patients with RRMS...
  3. doi request reprint Fingolimod therapy for multiple sclerosis
    Mary A Willis
    Neurological Institute, The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Neurol 33:37-44. 2013
    ..Additional clinical trial and postmarketing data suggest that fingolimod is a safe, effective, and well-tolerated treatment option when patients are selected and monitored appropriately...
  4. doi request reprint Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Lancet 380:1819-28. 2012
    ..We aimed to assess efficacy and safety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial...
  5. doi request reprint Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
    Jeffrey A Cohen
    Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Lancet Neurol 11:467-76. 2012
    ..A collaborative approach that involves academic experts, regulators, industry representitives, and funding agencies is needed to most effectively develop disability outcome measures...
  6. doi request reprint Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
    J A Cohen
    Mellen Center U 10, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:535-41. 2009
    ..v. methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNbeta-1a monotherapy...
  7. doi request reprint Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
    J A Cohen
    Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 14:370-82. 2008
    ....
  8. doi request reprint Emerging therapies for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Arch Neurol 66:821-8. 2009
    ..A sizable number of new agents are under investigation currently. This article reviews emerging agents that have shown promise in phase 2 trials...
  9. ncbi request reprint Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS
    J A Cohen
    Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Neurology 68:939-44. 2007
    ..To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple sclerosis...
  10. doi request reprint Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 362:402-15. 2010
    ..Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis...
  11. doi request reprint Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Neurol 69:759-77. 2011
    ..5 to 10x the approved 0.5 mg dose. Fingolimod's unique mechanism of action distinguishes it from all other currently approved MS therapies...
  12. ncbi request reprint Benefit of interferon beta-1a on MSFC progression in secondary progressive MS
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:679-87. 2002
    ..Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS...
  13. ncbi request reprint Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial
    J A Cohen
    The Mellen Center U10, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Arch Neurol 58:961-7. 2001
    ..The MSFC is the primary outcome measure in the ongoing multinational phase 3 trial of interferon beta-1a (Avonex) in patients with secondary progressive MS...
  14. doi request reprint The future of multiple sclerosis treatment
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Neurol Sci 277:S55-61. 2009
    ..The place that these therapies will come to occupy in future years will depend on their relative benefits and risks...
  15. doi request reprint Assessing disability progression with the Multiple Sclerosis Functional Composite
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA
    Mult Scler 15:984-97. 2009
    ..However, the clinical meaning of an MSFC Z-score change is not obvious. This study instead used MSFC component data to define a patient-specific disease progression event...
  16. ncbi request reprint Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    J Neuroimmunol 98:29-36. 1999
    ..Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary...
  17. ncbi request reprint A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta
    D R Smith
    Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Mult Scler 11:573-82. 2005
    ..To evaluate the efficacy and safety of combination therapy with pulse cyclophosphamide given with methylprednisolone (MP) and interferon beta (IFNbeta)-Ia in multiple sclerosis (MS) patients with active disease during IFNbeta monotherapy...
  18. ncbi request reprint Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study
    D M Miller
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Mult Scler 12:180-6. 2006
    ..The IMPACT data permit a detailed assessment of the relation between clinical and self-reported measures...
  19. ncbi request reprint Multiple sclerosis: the importance of early recognition and treatment
    R J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 68:157-71. 2001
    ..Several lines of evidence demonstrate that tissue damage occurs very early in the disease, and much of this damage is clinically silent...
  20. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  21. ncbi request reprint Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite
    L J Balcer
    Division of Neuro ophthalmology, Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Neurology 61:1367-73. 2003
    ..Visual dysfunction is one of the most common causes of disability in multiple sclerosis (MS). The Multiple Sclerosis Functional Composite (MSFC), a new clinical trial outcome measure, does not currently include a test of visual function...
  22. ncbi request reprint Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis
    B A C Cree
    Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
    Neurology 63:2039-45. 2004
    ..African American (AA) individuals are thought to develop multiple sclerosis (MS) less frequently than Caucasian American (CA) individuals...
  23. ncbi request reprint Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis
    M L Baier
    Center for Research Methodology and Biometrics, Cooper Institute, 14023 Denver West Parkway, 100, Golden, CO 80401, USA
    Neurology 64:992-5. 2005
    ..To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis Functional Composite (MSFC)...
  24. ncbi request reprint Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
    A D Goodman
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA rmc rochester edu
    Mult Scler 13:357-68. 2007
    ..To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg twice daily...
  25. ncbi request reprint Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
    H L Weiner
    Multiple Sclerosis Center, Brigham and Women s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston 02115, USA
    Mult Scler 8:142-54. 2002
    ..Cyclophosphamide is currently used in patients whose disease is not controlled by beta-interferon or glatiramer acetate and those with rapidly worsening MS...
  26. doi request reprint Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment
    C H Polman
    Department of Neurology, Free University Medical Center in Amsterdam, PO Box 4075, 1007 MB Amsterdam, The Netherlands
    Neurology 70:1134-40. 2008
    ..Guidance is also provided on the ethics of alternative trial designs and the balance between study subject burden and risk, scientific rationale and interpretability of trial outcomes...